Drugs / TAVO101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05298046 | May 2022 → Jun 2024 | — | Tavotek Biotherapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06176040 | Mar 2024 → Mar 2025 overdue | atopic eczema | Tavotek Biotherapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAVO101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06176040 ↗ |
| Route | Intravenous | “administered as an IV infusion” NCT05298046 ↗ |